Researchers completed a clinical trial testing whether tiny 2mg doses of psilocybin could safely improve mood in people with major depressive disorder. The study enrolled 39 participants who received either psilocybin microdoses or placebo in a crossover design. These sub-hallucinogenic amounts are far below recreational doses but may offer therapeutic benefits without psychedelic effects. The trial represents growing scientific interest in psychedelic medicine for mental health conditions that often accompany aging and chronic disease.
